Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Christian Thomas

Oncology
New England Cancer Specialists - Rock Row
11 Rock Row Ste 120, 
Westbrook, ME 
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
New England Cancer Specialists - Rock Row
11 Rock Row Ste 120, 
Westbrook, ME 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christian Thomas is an Oncologist in Westbrook, Maine. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Prostate Cancer, Familial Prostate Cancer, and Lung Cancer.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NH
Hospital Affiliations
Bridgton Hospital
Mainehealth Maine Medical Center
The Memorial Hospital
Northern Light Mercy Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

New England Cancer Specialists - Rock Row
11 Rock Row Ste 120, Westbrook, ME 04092
Call: 207-303-3300

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation
Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: August 16, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
A Phase I/II Open Label Clinical Trial Assessing Safety and Efficacy of Intravesical Instillation of VPM1002BC in Patients With Recurrent Non-muscle Invasive Bladder Cancer After Standard BCG Therapy
A Phase I/II Open Label Clinical Trial Assessing Safety and Efficacy of Intravesical Instillation of VPM1002BC in Patients With Recurrent Non-muscle Invasive Bladder Cancer After Standard BCG Therapy
Enrollment Status: Completed
Publish Date: April 13, 2023
Intervention Type: Drug
Study Drug: VPM1002BC
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

18 Total Publications

Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).
Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).
Journal: NPJ precision oncology
Published: June 11, 2023
View All 18 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Christopher G. Tretter
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Christopher G. Tretter
Hematology Oncology | Hematology | Oncology

Mainehealth

265 Western Ave, Suite 2, 
South Portland, ME 
 (46.3 miles away)
207-396-7606
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Tretter is a Hematologist Oncology specialist and a Hematologist in South Portland, Maine. Dr. Tretter is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma. Dr. Tretter is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Elizabeth Connelly
Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Elizabeth Connelly
Oncology

Memorial Hospital

3073 White Mountain Hwy, 
North Conway, NH 
 (71.0 miles away)
603-356-4904
Languages Spoken:
English
See accepted insurances

Elizabeth Connelly is an Oncologist in North Conway, New Hampshire. Dr. Connelly is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma, Angiosarcoma, and Paget Disease of the Breast.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Henry Sonneborn
Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Henry Sonneborn
Oncology

Wentworth-Douglass Hospital

789 Central Ave, 
Dover, NH 
 (11.2 miles away)
603-742-8787
Languages Spoken:
English
See accepted insurances

Henry Sonneborn is an Oncologist in Dover, New Hampshire. Dr. Sonneborn is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Throat Cancer, Testicular Yolk Sac Tumor, and Bone Marrow Aspiration.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Thomas's expertise for a condition
ConditionClose
    • Distinguished
    • Adult Soft Tissue Sarcoma
      Dr. Thomas is
      Distinguished
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Thomas is
      Distinguished
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Thomas is
      Distinguished
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Familial Prostate Cancer
      Dr. Thomas is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Lung Cancer
      Dr. Thomas is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Muscle Invasive Bladder Cancer
      Dr. Thomas is
      Distinguished
      . Learn about Muscle Invasive Bladder Cancer.
      See more Muscle Invasive Bladder Cancer experts
    View All 11 Distinguished Conditions
    • Advanced
    • Acute Myelomonocytic Leukemia
      Dr. Thomas is
      Advanced
      . Learn about Acute Myelomonocytic Leukemia.
      See more Acute Myelomonocytic Leukemia experts
    • Adult Immune Thrombocytopenia
      Dr. Thomas is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Agranulocytosis
      Dr. Thomas is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Bladder Cancer
      Dr. Thomas is
      Advanced
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Breast Cancer
      Dr. Thomas is
      Advanced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Childhood Iron Deficiency Anemia
      Dr. Thomas is
      Advanced
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    View All 31 Advanced Conditions
    • Experienced
    • Acute Mountain Sickness
      Dr. Thomas is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Thomas is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Thomas is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Thomas is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Thomas is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Alveolar Soft Part Sarcoma
      Dr. Thomas is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    View All 132 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved